GATA3 Monoclonal Antibody [1C1] 100 µg
- Known as:
- GATA3 Monoclonal Antibody [1C1] 100 µg
- Catalog number:
- ABB-2238-100
- Product Quantity:
- 100 µg
- Category:
- -
- Supplier:
- EpigenTek
- Gene target:
- GATA3 Monoclonal Antibody [1C1] 100 µ
Related genes to: GATA3 Monoclonal Antibody [1C1] 100 µg
- Gene:
- C1orf174 NIH gene
- Name:
- chromosome 1 open reading frame 174
- Previous symbol:
- -
- Synonyms:
- RP13-531C17.2
- Chromosome:
- 1p36.32
- Locus Type:
- gene with protein product
- Date approved:
- 2005-07-21
- Date modifiied:
- 2017-07-11
- Gene:
- CBR1 NIH gene
- Name:
- carbonyl reductase 1
- Previous symbol:
- CBR
- Synonyms:
- SDR21C1
- Chromosome:
- 21q22.12
- Locus Type:
- gene with protein product
- Date approved:
- 1991-02-20
- Date modifiied:
- 2016-10-05
- Gene:
- DLG1 NIH gene
- Name:
- discs large MAGUK scaffold protein 1
- Previous symbol:
- -
- Synonyms:
- SAP97, SAP-97, hdlg, DLGH1, dJ1061C18.1.1
- Chromosome:
- 3q29
- Locus Type:
- gene with protein product
- Date approved:
- 1995-05-04
- Date modifiied:
- 2016-05-24
- Gene:
- DNAAF4 NIH gene
- Name:
- dynein axonemal assembly factor 4
- Previous symbol:
- DYX1C1
- Synonyms:
- EKN1, FLJ37882, CILD25
- Chromosome:
- 15q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-10-10
- Date modifiied:
- 2017-03-20
- Gene:
- DNAAF4-CCPG1 NIH gene
- Name:
- DNAAF4-CCPG1 readthrough (NMD candidate)
- Previous symbol:
- DYX1C1-CCPG1
- Synonyms:
- -
- Chromosome:
- 15q21.3
- Locus Type:
- readthrough
- Date approved:
- 2011-09-23
- Date modifiied:
- 2017-03-23
Related products to: GATA3 Monoclonal Antibody [1C1] 100 µg
Related articles to: GATA3 Monoclonal Antibody [1C1] 100 µg
- The aim of this study was to evaluate the effect of supplementing in vitro culture medium of porcine zygotes with interleukin-4 (IL-4) on their developmental competence and quality. Cumulus-oocyte complexes (COCs) were matured and fertilized in vitro. The presumptive zygotes were then cultured in vitro for 7 days with different concentrations of IL-4 (25 pg/mL, 100 pg/mL, 25 ng/mL and 100 ng/mL) or without IL-4 (control). Cleavage and blastocyst formation rates were evaluated on days 2 and 7 of culture, respectively. On day 7 of IVC, some control and 25 pg/mL blastocysts were used to assess the expression of a panel of genes related to embryo quality by real-time quantitative PCR (RT-qPCR). The results did not show any positive effect of IL-4 on embryo developmental competence, regardless of its concentration. RT-qPCR revealed a significant downregulation of genes involved in cell cycle regulation (PCNA), DNA damage response and immune pathways (STAT6 and GATA3) in blastocysts treated with IL-4. In conclusion, supplementation of IVC medium with IL-4 did not improve the developmental competence of IVP embryos; however, IL-4 modulated the expression of stress- and immune-related genes in blastocysts. - Source: PubMed
Garcia-Canovas ManuelaTorregrosa-Fuentes MarcosLopez-Jara AdelinaParrilla InmaculadaRodriguez-Martinez HeribertoMartinez Emilio AGil Maria ACuello Cristina - GATA2 is a transcription factor that is essential for vascular and lymphatic development. GATA2 deficiency causes lymphatic malformations and lymphedema. Delayed lymphatic recanalization after popliteal lymph node removal in Gata2 heterozygous (Gata2+/-) mice is associated with collagen accumulation in the surrounding tissue. In this study, we investigated whether extracellular matrix (ECM) alterations contribute to lymphatic recanalization by analyzing subcutaneous tissue from Gata2+/- and Gata2 and Gata3 double heterozygous (Gata2+/-::Gata3+/-) mice. RNA-seq analysis revealed changes in ECM-related and adhesion-associated genes in both genotypes. Histological analyses demonstrated collagen accumulation and disorganized collagen bundles in Gata2+/-::Gata3+/- mice. Immunostaining further revealed reduced elastin fibers and decreased numbers of fibroblasts in subcutaneous tissues of Gata2+/- and Gata2+/-::Gata3+/- mice. These findings suggest that abnormalities in ECM organization, including altered collagen and elastin structures and reduced fibroblast populations, may underlie collagen accumulation and impaired lymphatic recanalization. Notably, Gata2+/-::Gata3+/- mice exhibited a patchwork-like dermal phenotype reflecting features of both single mutants, possibly owing to mosaic transcriptional regulation within the GATA gene network. The microenvironmental ECM structure plays an important role in lymphatic recanalization following lymphatic injury. - Source: PubMed
Publication date: 2026/09/30
Watanabe-Asaka TomomiHayashi MoyuruHarada-Norikane TakuyaNakamura MayuKouriki MayTakai JunUemura SatoshiHirose TakuoKawai Yoshiko - Urothelial carcinoma (UC) of the bladder remains a significant clinical challenge due to its high rates of recurrence and progression. Reliable biomarkers to predict tumor behaviour are still needed. GATA3 and HER2 have gained attention in this context, but their combined prognostic value has not been fully established. This study aims to evaluate the immunohistochemical expression of GATA3 and HER2 in bladder UC and to examine their association with key pathological parameters and patient outcomes. - Source: PubMed
Publication date: 2026/09/01
Mohammed Mona SaeedAbouhashim Nehal SelimElfeky Mariem Ahmed - Metastasis of invasive ductal carcinoma of the breast to the uterine cervix is rare, with only one report of a case occurring more than 20 years after the primary surgery. A 69-year-old woman presented with abnormal uterine cervical cytology (atypical glandular cells without tumor diathesis) 30 years after undergoing breast cancer surgery. Magnetic resonance imaging revealed a 38-mm cervical mass. Modified radical hysterectomy was performed. The resected specimen exhibited an immunohistochemical profile of GATA3(+)/mammaglobin(+)/PAX8(-), which definitively excluded primary cervical adenocarcinoma and confirmed the diagnosis of metastatic invasive ductal carcinoma. Crucially, although the primary tumor was hormone receptor-positive, cervical metastasis exhibited receptor conversion to HER2-positive status. This case underscores the importance of considering metastatic breast cancer in the differential diagnosis of cervical masses in breast cancer survivors regardless of the disease-free interval. This further highlights the necessity for receptor re-evaluation in metastatic lesions to guide appropriate targeted therapy. - Source: PubMed
Miyake TaroSasa HidenoriIto TsubasaWatanabe TakanoriSato TakakoOgata ShoTakano Masashi - Colorectal carcinoma (CRC) metastatic to the breast is exceedingly rare, with 46 cases compiled in a 2019 literature review and additional isolated reports since. The diagnostic challenge is substantially amplified in patients with a prior breast cancer history, in whom new breast lesions are reflexively attributed to recurrence rather than extramammary metastasis. A 71-year-old woman with a significant family history of malignancy presented with invasive lobular carcinoma of the left breast, treated with lumpectomy and hormonal therapy. Four months later, she was diagnosed with stage I endometrioid adenocarcinoma of the uterus; immunohistochemistry of the hysterectomy specimen revealed isolated PMS2 loss with preserved MLH1, MSH2, and MSH6 expression, and comprehensive germline testing of 35 hereditary cancer predisposition genes was negative, establishing a Lynch-like phenotype in that tumor. Approximately four years after her breast cancer diagnosis, she developed a maculopapular rash with skin thickening of the left breast, without a discrete mass; the clinical and mammographic presentation was concerning for inflammatory breast carcinoma. Punch biopsy demonstrated poorly differentiated adenocarcinoma with signet ring cell features, immunohistochemically positive for SATB2, CDX2, CK20, and CEA and negative for CK7, ER, PR, HER2, and GATA3, confirming colorectal origin and excluding breast cancer recurrence. Mismatch repair immunohistochemistry on the same specimen demonstrated retained expression of all four proteins, discordant with the endometrial primary and concordant with microsatellite instability-stable status and a tumor mutational burden of 3.7 mutations/Mb. Next-generation sequencing identified a TP53 splice region loss-of-function variant with RAS and BRAF wild-type status. Positron emission tomography revealed stage IV disease with hepatic metastasis, and colonoscopy identified synchronous cecal and recto-sigmoid masses. She was treated with four lines of systemic therapy and palliative radiation to the breast, and died approximately 20 months after the metastatic diagnosis. This case illustrates two points. First, any new breast lesion in a patient with prior malignancy requires histopathologic confirmation with comprehensive immunohistochemical analysis, as neither recurrence nor a primary breast process can be assumed. Second, mismatch repair status is a property of the individual tumor rather than of the patient; in patients with multiple primaries, each tumor requires independent testing, and molecular findings from one cannot be extrapolated to another. - Source: PubMed
Publication date: 2026/08/28
Walters Morgan LFigueroa Quast Andres